Please login to the form below

Not currently logged in

J&J recalls cold medications

Johnson & Johnson has recalled 9.3m bottles of Tylenol Multi-Symptom cold treatments because they fail to list the alcohol content on the front label

Continuing a string of recent recalls of over-the-counter products, Johnson & Johnson has recalled 9.3 million bottles of Tylenol Multi-Symptom cold treatments because they fail to list the alcohol content on the front label.

The recall, which was revealed in reports from the news service Bloomberg, is being conducted at the wholesale and retail level. No adverse events have been reported due to the labelling error, and consumers may continue to use products already in their possession.

The affected products, which are made by J&J's McNeil unit, are Tylenol Daytime 8 oz. Citrus Burst, Tylenol Severe 8 oz. Cool Burst and Tylenol Nighttime 8 oz. Cool Burst. The products are formulated with flavouring agents that contain a very small amount of alcohol. Regulations require that the alcohol be disclosed on the front of the bottle, but the recalled products instead list the information on the back label.

The relatively minor follows a string of problems this year, including a massive recall in April of more than 40 types of children's over-the-counter liquid medicines and a more recent recall of about 4m packages of Children's Benadryl allergy tablets. The company is currently under investigation by the US House Oversight and Government Reform Committee regarding its handling of the April recall.

26th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...